Skip to content

Portfolio

Partners HealthCare puts millions toward in-house innovation

January 13, 2016

The state’s largest health care system is putting an increased focus on financing homegrown innovations, with Partners HealthCare putting another $65 million in a fund used to invest in Partners technologies while opening the door to outside investors. The Partners Innovation Fund, created in 2007 with $35 million from Partners, was intended to progress Partners-developed…

Read More

Cambridge startup Editas plans to test IPO market for biotechs

January 8, 2016

Editas Medicine Inc., a Cambridge startup that is developing treatments to modify disease-causing genetic defects, plans to go public in a deal that could test the strength of the market for new biotech stocks. In a filing Monday with the Securities and Exchange Commission, two-year-old Editas did not specify the sales price range or when…

Read More

FierceBiotech's 2015 Fierce 15

January 8, 2016

Partners Innovation Fund portfolio company and PHS licensee Denali Therapeutics was selected for FierceBiotech’s 2015 highly competitive Fierce 15.

Read More

Quartet closes an upsized A round with a novel approach to pain

January 8, 2016

MGH spinout and PIF portfolio company, Quartet Medicine, added $6.25 million to its Series A fundraise, closing the round at $23.25 million as it moves toward clinical trials with a newfangled way of treating chronic pain.

Read More

Roche picks up a new autoimmune drug with $580M Adheron deal

January 8, 2016

10-9 – BWH spinout and PIF portfolio company, Adheron, has been acquired by Roch. Adheron is developing antibodies (currently in Phase I) targeting cadherin-11 for treatment of rheumatoid arthritis and other indications, and is based on technology developed by Michael Brenner, MD at BWH. Roche will be a great partner to move the product forward…

Read More

Blue Cross Blue Shield invests in Newton medical imaging company lifeIMAGE

January 8, 2016

10-2- PHS spin-off and Partners Innovation Fund portfolio company, lifeIMAGE, announced a $5 million strategic investment from Zaffre Investments, LLC, the investment arm of Blue Cross Blue Shield of Massachusetts. This investment follows the $17.5 million round of financing lifeIMAGE received in May.

Read More

FierceBiotech's 2015 Fierce 15

November 11, 2015

Whatever lies ahead for biotech in 2016, we can now look back on a 3-year-long stretch of good times for the industry. Venture groups have used the wave of biotech IPO exits and M&A deals to go back and raise more money from institutional investors. And as billions of dollars in fresh capital has converged…

Read More

Cambridge-based Editas gets $120M investment to advance genome editing

November 11, 2015

Kendall Square startup Editas Medicine, which aims to cure diseases by fixing disease-causing genes, today announced a $120 million investment, representing the second-largest venture capital rounds in Massachusetts so far this year. The Series B round comes from more than a dozen public and private investors, some of which — like New York City-based Deerfield…

Read More

GeneInsight wins Bio-IT World's Best Practice Award

April 10, 2013

Boston—Bio-IT World announced the winners of its ninth Best Practices Awards competition this morning in a plenary session at the 2013 Bio-IT World Conference & Expo in Boston. Grand prize winners were named in four life sciences categories highlighting best practices in genomics, cloud computing, big data in disease research, and big pharma data management…

Read More